Vistagen Therapeutics, Inc.
Vistagen Therapeutics, Inc. (Nasdaq: VTGN) is a clinical-stage therapeutics company developing medicines for social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. Its neuroscience pipeline includes five intranasal pherine candidates: fasedienol… From the company’s description.
Over the twelve months to Jun 30, 2026, Vistagen Therapeutics, Inc. reported revenue of $2.50M, up 287.2% from a year earlier, and a net loss of $67.62M. Operations used $62.30M in cash. In fiscal 2025, it reported revenue of $1.27M, up 161.1% from fiscal 2024, and a net loss of $69.69M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Vistagen Therapeutics, Inc. does
In the company’s own words
Vistagen Therapeutics, Inc. (Nasdaq: VTGN) is a clinical-stage therapeutics company developing medicines for social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. Its neuroscience pipeline includes five intranasal pherine candidates: fasedienol for acute social anxiety disorder, itruvone for major depressive disorder, refisolone for menopausal vasomotor symptoms, PH15 for mental-fatigue-related impairment, and PH284 for cancer cachexia. The candidates are designed to act through nasal sensory receptors and neural circuits; Vistagen also holds AV-101, an oral candidate targeting NMDAR-related disorders. The company’s most advanced program, fasedienol, is in Phase 3 development, while its other candidates are in earlier clinical development or under evaluation for further development. Vistagen licenses fasedienol development and commercialization rights in parts of Asia to AffaMed Therapeutics and retains rights elsewhere. In fiscal 2026, the company reported no commercial product sales and focused on research and development. Its website is www.vistagen.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- March
- CIK
- 1411685
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Vistagen Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Vistagen Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Vistagen Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Vistagen Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Vistagen Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”